Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Closing of Non-Brokered Private Placement for $1.7 Million. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News MacroGenics Inc MGNX

Healthcare Biotechnology
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as... see more

Current News (NDAQ:MGNX)

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

GlobeNewswire November 25, 2025

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

GlobeNewswire November 12, 2025

MacroGenics to Participate in the Stifel 2025 Healthcare Conference

GlobeNewswire November 6, 2025

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 2, 2025

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

GlobeNewswire August 14, 2025

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

GlobeNewswire August 13, 2025

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

GlobeNewswire June 10, 2025

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

GlobeNewswire June 3, 2025

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

GlobeNewswire May 13, 2025
View More News ››

Opinion & Analysis (NDAQ:MGNX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MGNX)

MacroGenics, Inc. (NASDAQ:MGNX) Promising Pipeline and Impro

http://beyondspx.com/2024/07/31/macrogenics-inc-nasdaqmgnx-promising-pipeline-and-improved-safety-profile-for-lead-adc-candidate/
MikeTester - August 2, 2024

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

$NKTR $MGNX $CTMX $IDYA $ALKS Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7,650...
AviseAnalytics - January 26, 2022
View more Bullboard ››

Mink Ventures Corp.

Mink Ventures Corp.

Mink Ventures Corporation engages in the acquisition, exploration, and development of mineral property interests in Canada ...
View More »

Podcasts